A detailed history of Royal Bank Of Canada transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 23,603 shares of OLMA stock, worth $207,234. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,603
Previous 12,631 86.87%
Holding current value
$207,234
Previous $136,000 106.62%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.41 - $16.46 $114,218 - $180,599
10,972 Added 86.87%
23,603 $281,000
Q2 2024

Aug 14, 2024

BUY
$8.73 - $13.99 $104,864 - $168,047
12,012 Added 1940.55%
12,631 $136,000
Q1 2024

Nov 05, 2024

SELL
$10.95 - $16.62 $131,531 - $199,639
-12,012 Reduced 95.1%
619 $7,000
Q1 2024

May 15, 2024

SELL
$10.95 - $16.62 $82,409 - $125,082
-7,526 Reduced 92.4%
619 $7,000
Q4 2023

Feb 14, 2024

BUY
$10.53 - $17.14 $38,297 - $62,338
3,637 Added 80.68%
8,145 $114,000
Q3 2023

Nov 14, 2023

BUY
$8.19 - $12.98 $13,980 - $22,156
1,707 Added 60.94%
4,508 $55,000
Q2 2023

Aug 14, 2023

BUY
$3.22 - $9.65 $7,866 - $23,574
2,443 Added 682.4%
2,801 $25,000
Q1 2023

May 15, 2023

BUY
$2.55 - $4.97 $703 - $1,371
276 Added 336.59%
358 $1,000
Q4 2022

Feb 14, 2023

BUY
$2.27 - $3.76 $18 - $30
8 Added 10.81%
82 $0
Q3 2022

Nov 14, 2022

BUY
$2.72 - $5.88 $201 - $435
74 New
74 $0
Q2 2022

Aug 15, 2022

SELL
$2.04 - $4.61 $3,215 - $7,265
-1,576 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$3.89 - $9.43 $459,451 - $1.11 Million
-118,111 Reduced 98.68%
1,576 $7,000
Q4 2021

Feb 14, 2022

BUY
$8.75 - $30.71 $1.02 Million - $3.6 Million
117,098 Added 4522.9%
119,687 $1.12 Million
Q3 2021

Nov 15, 2021

BUY
$22.96 - $30.13 $27,322 - $35,854
1,190 Added 85.06%
2,589 $71,000
Q2 2021

Aug 16, 2021

BUY
$21.15 - $36.14 $29,588 - $50,559
1,399 New
1,399 $39,000

Others Institutions Holding OLMA

About Olema Pharmaceuticals, Inc.


  • Ticker OLMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,419,600
  • Market Cap $355M
  • Description
  • Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...
More about OLMA
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.